Listed

Kyverna Therapeutics, Inc.

KYTXNasdaqCIK 1994702HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$39.6m, Q2 FY2026
Net income−$38.3m, Q2 FY2026
Kyverna Therapeutics, Inc., income statement, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m13.6Research and development, period not labelled, three months to 2023-09-30$13.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure17.2Research and development, period not labelled, three months to 2023-12-31$17.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-27, accession 0000950170-25-046074. Derived: 12-month figure less the 9-month figure.Report this figure22.5Research and development, Q1 FY2024, three months to 2024-03-31$22.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure27.3Research and development, Q2 FY2024, three months to 2024-06-30$27.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-12, accession 0000950170-25-107321.Report this figure29.2Research and development, Q3 FY2024, three months to 2024-09-30$29.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure33.5Research and development, Q4 FY2024, three months to 2024-12-31$33.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure37.4Research and development, Q1 FY2025, three months to 2025-03-31$37.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure35.8Research and development, Q2 FY2025, three months to 2025-06-30$35.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure30.5Research and development, Q3 FY2025, three months to 2025-09-30$30.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure30.0Research and development, Q4 FY2025, three months to 2025-12-31$30.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure30.1Research and development, Q1 FY2026, three months to 2026-03-31$30.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure24.8Research and development, Q2 FY2026, three months to 2026-06-30$24.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Operating income$m(16.3)Operating income, period not labelled, three months to 2023-09-30−$16.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure(21.4)Operating income, period not labelled, three months to 2023-12-31−$21.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-27, accession 0000950170-25-046074. Derived: 12-month figure less the 9-month figure.Report this figure(29.4)Operating income, Q1 FY2024, three months to 2024-03-31−$29.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure(33.4)Operating income, Q2 FY2024, three months to 2024-06-30−$33.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0000950170-25-107321.Report this figure(38.8)Operating income, Q3 FY2024, three months to 2024-09-30−$38.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure(41.0)Operating income, Q4 FY2024, three months to 2024-12-31−$41.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure(47.4)Operating income, Q1 FY2025, three months to 2025-03-31−$47.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure(44.4)Operating income, Q2 FY2025, three months to 2025-06-30−$44.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure(38.7)Operating income, Q3 FY2025, three months to 2025-09-30−$38.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure(39.3)Operating income, Q4 FY2025, three months to 2025-12-31−$39.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure(41.4)Operating income, Q1 FY2026, three months to 2026-03-31−$41.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure(39.6)Operating income, Q2 FY2026, three months to 2026-06-30−$39.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Interest expense$m0.1Interest expense, period not labelled, three months to 2023-09-30$50.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure0.0Interest expense, period not labelled, three months to 2023-12-31$47.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2025-03-27, accession 0000950170-25-046074. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2024, three months to 2024-03-31$44.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-14, accession 0000950170-24-059628.Report this figure0.0Interest expense, Q2 FY2024, three months to 2024-06-30$39.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-12, accession 0000950170-24-095462.Report this figure0.0Interest expense, Q3 FY2024, three months to 2024-09-30$32.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$27.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$25.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$14.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure0.0Interest expense, Q3 FY2025, three months to 2025-09-30$7.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure0.4Interest expense, Q4 FY2025, three months to 2025-12-31$444.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure0.7Interest expense, Q1 FY2026, three months to 2026-03-31$667.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure0.7Interest expense, Q2 FY2026, three months to 2026-06-30$674.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Net income$m(15.5)Net income, period not labelled, three months to 2023-09-30−$15.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure(20.7)Net income, period not labelled, three months to 2023-12-31−$20.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-27, accession 0000950170-25-046074. Derived: 12-month figure less the 9-month figure.Report this figure(26.7)Net income, Q1 FY2024, three months to 2024-03-31−$26.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure(28.8)Net income, Q2 FY2024, three months to 2024-06-30−$28.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure(34.5)Net income, Q3 FY2024, three months to 2024-09-30−$34.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure(37.5)Net income, Q4 FY2024, three months to 2024-12-31−$37.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure(44.6)Net income, Q1 FY2025, three months to 2025-03-31−$44.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure(42.1)Net income, Q2 FY2025, three months to 2025-06-30−$42.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure(36.8)Net income, Q3 FY2025, three months to 2025-09-30−$36.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure(37.8)Net income, Q4 FY2025, three months to 2025-12-31−$37.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure(39.7)Net income, Q1 FY2026, three months to 2026-03-31−$39.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure(38.3)Net income, Q2 FY2026, three months to 2026-06-30−$38.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Diluted EPS$ per share(23.27)Diluted EPS, period not labelled, three months to 2023-09-30−$23.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figurenot reported(1.12)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure(0.67)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0000950170-25-107321.Report this figure(0.80)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figurenot reported(1.03)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure(0.97)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure(0.85)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figurenot reported(0.66)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure(0.63)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Basic EPS$ per share(23.27)Basic EPS, period not labelled, three months to 2023-09-30−$23.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figurenot reported(1.12)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure(0.67)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.67 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0000950170-25-107321.Report this figure(0.80)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figurenot reported(1.03)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure(0.97)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.97 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure(0.85)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.85 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figurenot reported(0.66)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure(0.63)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure

Balance sheet

Cash and equivalents$31.8m, Q2 FY2026
Long-term debt$24.9m, Q2 FY2026
Shareholders' equity$165.5m, Q2 FY2026
Kyverna Therapeutics, Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m23.0Cash and equivalents, period not labelled, at 2023-09-30$23.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure34.6Cash and equivalents, period not labelled, at 2023-12-31$34.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-27, accession 0000950170-25-046074.Report this figure224Cash and equivalents, Q1 FY2024, at 2024-03-31$224.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure132Cash and equivalents, Q2 FY2024, at 2024-06-30$131.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0000950170-25-107321.Report this figure105Cash and equivalents, Q3 FY2024, at 2024-09-30$104.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure96.6Cash and equivalents, FY2024, at 2024-12-31$96.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-26, accession 0001193125-26-126242.Report this figure56.9Cash and equivalents, Q1 FY2025, at 2025-03-31$56.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure53.4Cash and equivalents, Q2 FY2025, at 2025-06-30$53.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure34.2Cash and equivalents, Q3 FY2025, at 2025-09-30$34.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure124Cash and equivalents, FY2025, at 2025-12-31$124.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure32.2Cash and equivalents, Q1 FY2026, at 2026-03-31$32.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure31.8Cash and equivalents, Q2 FY2026, at 2026-06-30$31.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Current assets$mnot reported60.7Current assets, period not labelled, at 2023-12-31$60.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-27, accession 0000950170-25-046074.Report this figure375Current assets, Q1 FY2024, at 2024-03-31$375.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-14, accession 0000950170-24-059628.Report this figure349Current assets, Q2 FY2024, at 2024-06-30$348.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-12, accession 0000950170-24-095462.Report this figure325Current assets, Q3 FY2024, at 2024-09-30$325.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure291Current assets, FY2024, at 2024-12-31$290.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-26, accession 0001193125-26-126242.Report this figure248Current assets, Q1 FY2025, at 2025-03-31$247.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure214Current assets, Q2 FY2025, at 2025-06-30$214.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107321.Report this figure175Current assets, Q3 FY2025, at 2025-09-30$174.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure283Current assets, FY2025, at 2025-12-31$283.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure242Current assets, Q1 FY2026, at 2026-03-31$241.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure207Current assets, Q2 FY2026, at 2026-06-30$206.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Total assets$mnot reported75.2Total assets, period not labelled, at 2023-12-31$75.2m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-27, accession 0000950170-25-046074.Report this figure390Total assets, Q1 FY2024, at 2024-03-31$390.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-14, accession 0000950170-24-059628.Report this figure363Total assets, Q2 FY2024, at 2024-06-30$363.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-12, accession 0000950170-24-095462.Report this figure339Total assets, Q3 FY2024, at 2024-09-30$339.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure305Total assets, FY2024, at 2024-12-31$304.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-26, accession 0001193125-26-126242.Report this figure261Total assets, Q1 FY2025, at 2025-03-31$260.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure227Total assets, Q2 FY2025, at 2025-06-30$226.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0000950170-25-107321.Report this figure187Total assets, Q3 FY2025, at 2025-09-30$187.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure294Total assets, FY2025, at 2025-12-31$293.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure257Total assets, Q1 FY2026, at 2026-03-31$257.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure220Total assets, Q2 FY2026, at 2026-06-30$219.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Current liabilities$mnot reported19.9Current liabilities, period not labelled, at 2023-12-31$19.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-27, accession 0000950170-25-046074.Report this figure21.9Current liabilities, Q1 FY2024, at 2024-03-31$21.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-14, accession 0000950170-24-059628.Report this figure23.5Current liabilities, Q2 FY2024, at 2024-06-30$23.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-12, accession 0000950170-24-095462.Report this figure31.0Current liabilities, Q3 FY2024, at 2024-09-30$31.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure33.8Current liabilities, FY2024, at 2024-12-31$33.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-26, accession 0001193125-26-126242.Report this figure33.3Current liabilities, Q1 FY2025, at 2025-03-31$33.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure39.8Current liabilities, Q2 FY2025, at 2025-06-30$39.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-107321.Report this figure33.9Current liabilities, Q3 FY2025, at 2025-09-30$33.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure36.5Current liabilities, FY2025, at 2025-12-31$36.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure29.7Current liabilities, Q1 FY2026, at 2026-03-31$29.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure22.8Current liabilities, Q2 FY2026, at 2026-06-30$22.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Total liabilities$mnot reported26.0Total liabilities, period not labelled, at 2023-12-31$26.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-27, accession 0000950170-25-046074.Report this figure29.0Total liabilities, Q1 FY2024, at 2024-03-31$29.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-14, accession 0000950170-24-059628.Report this figure29.6Total liabilities, Q2 FY2024, at 2024-06-30$29.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-12, accession 0000950170-24-095462.Report this figure36.5Total liabilities, Q3 FY2024, at 2024-09-30$36.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure38.1Total liabilities, FY2024, at 2024-12-31$38.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-26, accession 0001193125-26-126242.Report this figure36.6Total liabilities, Q1 FY2025, at 2025-03-31$36.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure42.1Total liabilities, Q2 FY2025, at 2025-06-30$42.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0000950170-25-107321.Report this figure35.2Total liabilities, Q3 FY2025, at 2025-09-30$35.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure61.6Total liabilities, FY2025, at 2025-12-31$61.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure61.4Total liabilities, Q1 FY2026, at 2026-03-31$61.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure54.3Total liabilities, Q2 FY2026, at 2026-06-30$54.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported24.7Long-term debt, FY2025, at 2025-12-31$24.7m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figurenot reported24.9Long-term debt, Q2 FY2026, at 2026-06-30$24.9m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure
Shareholders' equity$m(112)Shareholders' equity, period not labelled, at 2023-09-30−$111.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure(13.1)Shareholders' equity, period not labelled, at 2023-12-31−$13.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-26, accession 0001193125-26-126242.Report this figure361Shareholders' equity, Q1 FY2024, at 2024-03-31$361.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure334Shareholders' equity, Q2 FY2024, at 2024-06-30$333.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure303Shareholders' equity, Q3 FY2024, at 2024-09-30$302.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure267Shareholders' equity, FY2024, at 2024-12-31$266.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure224Shareholders' equity, Q1 FY2025, at 2025-03-31$224.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure184Shareholders' equity, Q2 FY2025, at 2025-06-30$184.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure152Shareholders' equity, Q3 FY2025, at 2025-09-30$151.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure232Shareholders' equity, FY2025, at 2025-12-31$232.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure196Shareholders' equity, Q1 FY2026, at 2026-03-31$195.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure166Shareholders' equity, Q2 FY2026, at 2026-06-30$165.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure

Cash flow

Operating cash flow−$40.3m, Q2 FY2026
Capital expenditure−$1.0k, Q4 FY2025
Kyverna Therapeutics, Inc., cash flow, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(11.1)Operating cash flow, period not labelled, three months to 2023-09-30−$11.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0000950170-24-126366. Derived: 9-month figure less the 6-month figure.Report this figure(18.6)Operating cash flow, period not labelled, three months to 2023-12-31−$18.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-27, accession 0000950170-25-046074. Derived: 12-month figure less the 9-month figure.Report this figure(25.5)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$25.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure(24.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$24.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0000950170-25-107321. Derived: 6-month figure less the 3-month figure.Report this figure(27.5)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$27.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277584. Derived: 9-month figure less the 6-month figure.Report this figure(37.1)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$37.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure(44.9)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$44.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure(31.9)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$31.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344607. Derived: 6-month figure less the 3-month figure.Report this figure(43.3)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$43.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277584. Derived: 9-month figure less the 6-month figure.Report this figure(33.5)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$33.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure(41.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$41.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure(40.3)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$40.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344607. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.3Capital expenditure, period not labelled, three months to 2023-09-30$256.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0000950170-24-126366. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, period not labelled, three months to 2023-12-31$334.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-27, accession 0000950170-25-046074. Derived: 12-month figure less the 9-month figure.Report this figure0.5Capital expenditure, Q1 FY2024, three months to 2024-03-31$543.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure1.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-12, accession 0000950170-25-107321. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$102.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-277584. Derived: 9-month figure less the 6-month figure.Report this figure0.5Capital expenditure, Q4 FY2024, three months to 2024-12-31$532.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-344607. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-277584. Derived: 9-month figure less the 6-month figure.Report this figure(0.0)Capital expenditure, Q4 FY2025, three months to 2025-12-31−$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001193125-26-126242. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)60.90m, Q2 FY2026
Kyverna Therapeutics, Inc., shares, quarterly
Line itemUnitperiod not labelled2023-03-31period not labelled2023-06-30period not labelled2023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.9Diluted shares (weighted), period not labelled, three months to 2023-03-31921,260 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-14, accession 0000950170-24-059628.Report this figure0.6Diluted shares (weighted), period not labelled, three months to 2023-06-30627,589 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-12, accession 0000950170-24-095462.Report this figure0.7Diluted shares (weighted), period not labelled, three months to 2023-09-30664,656 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0000950170-24-126366.Report this figure23.8Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3123,754,062 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0000950170-25-070325.Report this figure43.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3043,125,709 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0000950170-25-107321.Report this figure43.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3043,155,858 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure43.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3143,215,577 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure43.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3043,225,365 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure43.4Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3043,415,367 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277584.Report this figure60.4Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3160,434,200 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-219397.Report this figure60.9Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3060,896,872 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure

Shares outstanding: 61.84mShares outstanding, period not labelled, at 2026-08-0361,843,444 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344607.Report this figure at Aug 3, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.